Drug Discovery World

APRIL 6, 2023

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Protein 52

Protein Clinical Trials Clinical Trials Antibody 52

The Pharma Data

JULY 27, 2021

Acquisition Complements Amgen’s Antibody Research Capabilities Across Therapeutic Areas Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients With Advanced Prostate Cancer. billion in cash. Reese, M.D., executive vice president of Research and Development at Amgen.

Production 52

Production Antibody Sales Manufacturing 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

OCTOBER 3, 2022

He holds a PhD in Medicine from Leiden University, and an MSc in Bioinformatics and Artificial Intelligence from Brunel University. He has over 12 years of experience in the healthcare sector and is the author of over 30 peer- reviewed scientific articles. Fellowship Programme.

Drugs 52

Drugs Scientist Bioinformatics Medicine 52

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Hiroki Shirai, PhD, Coordinator, RIKEN Center for Computational Science, on: ‘Applying deep learning anomaly detection to antibody structures’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 4, 2022

Throughout 2022, Exscientia has progressed AI-driven capabilities for virtual biologics design, such as human antibodies, and is now establishing an automated biologics laboratory in Oxford to internally generate and profile novel antibodies. . The binding site of the antibody consists of two chains (heavy and light).

Antibody 52

Antibody Bioinformatics Engineer Protein 52

Drug Discovery World

NOVEMBER 15, 2022

Applications: The ability to synthesise longer, accurate DNA sequences opens up a vast array of application possibilities: generating CRISPR libraries, in situ hybridisation probes, antibody libraries, vaccines, and so on, along with the ability to engineer metabolic pathways, microbes, and plants. .

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

NOVEMBER 30, 2023

The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. It was presented by Lei Shi, PhD, Senior Vice President, R&D, Biointron Biological, titled: ‘Accelerating early discovery through HTP and high-speed antibody production’.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

JULY 11, 2023

In another published report 2 , a biotech company needed to improve its centrifugation step during monoclonal antibody (mAb) harvesting. This knowledge enabled cell line engineering campaigns that boosted yield and stability across various production bottlenecks.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

APRIL 29, 2024

He holds a PhD in Chemistry for early work on antibody drug conjugates in 1987 and was awarded the Bioprocessing Lifetime Achievement Award in 2021. He has a PhD in Bioinformatics from the University of Cambridge.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

pharmaphorum

MARCH 28, 2022

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise antibodies for targeted therapies. . From there, they evaluate what kind of antibodies are produced. ” The Application .

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

Drug Discovery World

SEPTEMBER 7, 2022

Let’s take a relatively simple example: with antibody engineering, you might start with an antibody, its target, and its binding affinity. Rather than analysing data, your data science or bioinformatics team will be spending their time linking, reconciling, and cleaning data. …on a flexible software platform .

Scientist 52

Scientist Life Science Antibody Protein 52

The Pharma Data

SEPTEMBER 1, 2020

Presentation Topic: Biomarkers and Bioinformatics. Patients without a healthcare professional-confirmed history of varicella (chickenpox), or without documentation of a full course of vaccination against varicella zoster virus (VZV), should be tested for antibodies to VZV before initiating ZEPOSIA. Author: Harris. Author: Healy.

Trials 52

Trials Clinical Trials Clinical Trials Vaccination 52

XTalks

NOVEMBER 7, 2022

Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs. Optimal methods for bioinformatic analysis are still needed. This is a negative CTC selection technique because CD45 markers are used to remove white blood cells from the sample, leaving CTCs behind.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

APRIL 21, 2023

Atrandi Biosciences’ novel technology platform enables researchers to gain insights into the biology of single cells, offering immediate applications in single-cell sequencing, drug and antibody discovery, functional metagenomics, microbial analysis, directed evolution, and synthetic biology.

Doctors 52

Doctors Doctor Genetics In-Vitro 52